Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation

Iosif B. Mikhel,Elena O. Bakhrushina,Danila A. Petrusevich,Andrey A. Nedorubov,Svetlana A. Appolonova,Natalia E. Moskaleva,Natalia B. Demina,Svetlana I. Kosenkova,Mikhail A. Parshenkov,Ivan I. Krasnyuk,Ivan I. Krasnyuk
DOI: https://doi.org/10.3390/pharmaceutics16091125
IF: 6.525
2024-08-28
Pharmaceutics
Abstract:Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.
pharmacology & pharmacy
What problem does this paper attempt to address?